Snowden Capital Advisors’s Xenon Pharmaceuticals XENE Stock Holding History

Snowden Capital Advisors’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$246K	Buy	+4,223	New	+$195K	0.01%	1111
2024 Q3	–	Sell	-5,511	Closed	-$215K	–	1262
2024 Q2	$215K	Buy	5,511 +12	+0.2%	+$480	0.01%	1116
2024 Q1	$237K	Sell	5,499 -224	-4%	-$10.3K	0.01%	1067
2023 Q4	$264K	Sell	5,723 -142	-2%	-$5.02K	0.01%	962
2023 Q3	$200K	Sell	5,865 -131	-2%	-$4.9K	0.01%	1022
2023 Q2	$231K	Buy	+5,996	New	+$238K	0.01%	1051

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Snowden Capital Advisors's XENE Position: Q1 2026 in Review

Snowden Capital Advisors opened a new position in Xenon Pharmaceuticals (XENE) in Q1 2026: 4,223 shares worth $246K. The stake represents 0.01% of the portfolio and ranks #1111 among its holdings. This is a return to the name: Snowden Capital Advisors previously reported a position in XENE as recently as Q2 2024.

Snowden Capital Advisors first reported a position in XENE in Q2 2023 and has held it in 6 quarters since. The position peaked at $264K in Q4 2023. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

Snowden Capital Advisors held 4,223 shares of Xenon Pharmaceuticals worth $246K as of Q1 2026.
Xenon Pharmaceuticals was a new Snowden Capital Advisors position in Q1 2026.
Xenon Pharmaceuticals made up 0.01% of Snowden Capital Advisors's portfolio in Q1 2026, its #1111 holding.
Snowden Capital Advisors first reported a position in Xenon Pharmaceuticals in Q2 2023 and has held it in 6 quarters since.
Snowden Capital Advisors's Xenon Pharmaceuticals position peaked at $264K in Q4 2023.
290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on Snowden Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.